Intelligence Β· Clinical Pipeline
Phase II Pipeline Programs
Proof-of-concept and dose-finding clinical programs in Phase II development.
- Programs
- 7,238
Quick answer
NovaPharmaNews tracks 7,238 phase ii pharmaceutical pipeline programs from ClinicalTrials.gov. Proof-of-concept and dose-finding clinical programs in Phase II development.
Top sponsors
- Chinese Academy of 432 programs
- BRIGHT MINDS BIOSCIENCES 393 programs
- First People's Hospital 375 programs
- United Therapeutics Europe 336 programs
- Takeda 335 programs
- Anaxis Pharma 223 programs
- George Institute for 187 programs
- Regeneron UK 176 programs
- Teva Pharma 126 programs
- Novartis India 121 programs
- Telethon Foundation 119 programs
- Disc Medicine 106 programs
-
SB-509
SANGAMO THERAPEUTICS, INC
Diabetes Mellitus, Type 1
4 trials -
SB-728-T
SANGAMO THERAPEUTICS, INC
HIV
2 trials -
SB-728mR-T
SANGAMO THERAPEUTICS, INC
Human Immunodeficiency Virus (HIV)
1 trial -
SB-913
SANGAMO THERAPEUTICS, INC
Mucopolysaccharidosis II
1 trial -
SB497115
GlaxoSmithKline
Thrombocytopaenia
1 trial -
SB497115
GlaxoSmithKline
Purpura, Thrombocytopaenic, Idiopathic
1 trial -
SBRT combined with Nimotuzumab followed by Tislelizumab
The First People's Hospital of Lianyungang
Nasopharyngeal Cancinoma (NPC)
1 trial -
SBRT combined with PD-1 inhibitors and thoracic hyperthermia
The First People's Hospital of Lianyungang
Stereotactic Body Radiation Therapy; PD-1 Inhibitor; Hyperthermia; NSCLC
1 trial -
SBRT combined with Tislelizumab followed by Tislelizumab
Zibo Municipal Hospital
NSCLC
1 trial -
SCB01A
Biotech Pharmaceutical Co.,
Head and Neck Neoplasms
1 trial -
SCD-044 Tablets 0.1mg, SCD-044 Tablets 0.6mg, SCD-044 Tablets 0.3mg, SCD-044 Tablets 1.0mg, placebo to match SCD-044 tablets
Lacuna Pharma Pty Ltd
atopic dermatitis
1 trial -
SCD-044 Tablets 0.3mg, SCD-044 Tablets 0.6mg, SCD-044 Tablets 1.0mg, SCD-044 Tablets 0.1mg, placebo to match SCD-044 tablets
Lacuna Pharma Pty Ltd
moderate to severe plaque psoriasis
1 trial -
SCENESSE 16 mg implant
Clinuvel Europe Limited
Erythropoietic Protoporphyria (EPP)
1 trial -
SD-101 dermal cream (6%)
BRIGHT MINDS BIOSCIENCES INC.
Epidermolysis Bullosa
1 trial -
SDREGN2810
Regeneron UK Limited
Advanced Non-Small Cell Lung Carcinoma
1 trial -
SDX-101 (R-Etodolac)
Teva Pharma GmbH
Multiple Myeloma
1 trial -
SDX-105
Teva Pharma GmbH
Non-Hodgkin's Lymphoma
1 trial -
SDZ MSL-109
Ultragenyx UK Limited
Cytomegalovirus Infections
1 trial -
SELINEXOR
Karyopharm Therapeutics Inc
Myelofibrosis
1 trial -
SELPERCATINIB, SELPERCATINIB
Wuhan Createrna Science and Technology Co., Ltd
Male or female patients age 12 years or older with a locally advanced or metastatic solid tumor with evidence of a RET gene alteration in tumor and/or blood.
1 trial -
SELPERCATINIB, Selpercatinib, Selpercatinib, SELPERCATINIB, Selpercatinib
Wuhan Createrna Science and Technology Co., Ltd
Pediatric Patients with Advanced RET-Altered Solid or Primary Central Nervous System Tumors
1 trial -
SELUMETINIB, CASODEX 50 mg compresse rivestite con film, OLAPARIB
Istituto Gentili S.r.l.
Metastatic breast cancer
1 trial -
SELUMETINIB, SELUMETINIB, Selumetinib, Selumetinib
AstraZeneca AB
Neurofibromatosis Type 1 (NF1) Related Plexiform Neurofibromas (PN)
1 trial -
SENS-401 (R-Azasetron Besylate)
Orion Laboratories Pty.
Hearing Loss
1 trial -
SER-109
Seres Therapeutics
Clostridium Difficile
1 trial -
SERETIDE Rotacaps
GlaxoSmithKline
Asthma
1 trial -
SG+I
Xiyuan Hospital of China Academy of Chinese Medical Sciences
TNBC, Triple Negative Breast Cancer
1 trial -
SGT-001
Solid Biosciences
Duchenne Muscular Dystrophy
1 trial -
SHJ002/Vehicle
Biotech Pharmaceutical Co.,
Dry Eye Disease
1 trial -
SHP611
Shire
Metachromatic Leukodystrophy (MLD)
1 trial -
SHP611
Takeda
Metachromatic Leukodystrophy (MLD)
1 trial -
SHP626
Mirum Pharmaceuticals International B.V.
Non-Alcoholic Steatohepatitis
3 trials -
SHP648
Takeda
Hemophilia B
1 trial -
SHP655
Takeda
Acquired Thrombotic Thrombocytopenic Purpura (aTTP)
1 trial -
SHR-1139 Injection
The First People's Hospital of Lianyungang
Pyoderma Gangrenosum
1 trial -
SHR-1210
The First People's Hospital of Lianyungang
Resectable Esophageal Squamous Cell Carcinoma
1 trial -
SHR-1210
Hospital Authority, Hong Kong
Renal Cell Carcinoma
1 trial -
SHR-1701
The First People's Hospital of Lianyungang
Gastric Adenocarcinoma
1 trial -
SHR-1701 Combined With Fluazopalil
Hunan Province Tumor Hospital
Non-Small Cell Lung Cancer
1 trial -
SHR-A1921 injection and adebrelimab injection
Xiyuan Hospital of China Academy of Chinese Medical Sciences
NSCLC
1 trial -
SHR20004
Jian Li
Obesity
1 trial -
SHR2554/AZA + Overlapped TBF
The First People's Hospital of Lianyungang
Acute Myeloid Leukemia
1 trial -
SI-B001
Sichuan Baili Pharmaceutical Co.,
Non Small Cell Lung Cancer
1 trial -
SIKLOS PAEDIATRIC 50mg dispersible tablets
THERAVIA
Sickle Cell Disease
1 trial -
SILIMARIN 200 mg compresse rivestite, Kisqali 200 mg film-coated tablets
Fondazione Telethon ETS
hormone receptor positive, HER2-negative breast cancer
1 trial -
SILTUXIMAB , PREDNISOLONE , CYCLOPHOSPHAMIDE , CARBOPLATIN , PARACETAMOL , ETOPOSIDE , VINCRISTINE , LENALIDOMIDE , DIPHENHYDRAMINE , GEMCITABINE , PREDNISONE , OXALIPLATIN , TOCILIZUMAB , Epcoritamab, Epcoritamab, DEXAMETHASONE , DOXORUBICIN , CYTARABINE , RITUXIMAB , IFOSFAMIDE , ANAKINRA , BENDAMUSTINE
Genmab A/S
Lymphoma of B-cell origin
1 trial -
SILTUXIMAB, Tarlatamab, Tarlatamab
Amgen
Small Cell Lung Cancer (SCLC)
1 trial -
SION-719
Sionna Therapeutics
Cystic Fibrosis (CF)
1 trial
Frequently asked questions
How many Phase II pipeline programs are in the directory?
7,238 published programs match this development stage in our ClinicalTrials.gov index.
What defines this pipeline stage?
Phase and status reflect ClinicalTrials.gov registry fields at last sync. See our clinical trial phases reference for methodology.
Data attribution: Data sources Β· All pipeline programs